MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To judge many intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Most important demo goals had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exploratory https://altonj555ugr8.wiki-cms.com/user